Literature DB >> 17977053

Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease.

Daniel Alvira1, Isidre Ferrer, Javier Gutierrez-Cuesta, Beatriz Garcia-Castro, Merce Pallàs, Antoni Camins.   

Abstract

The mechanisms involved in neuronal loss in Parkinson's disease (PD) are not known, although recent studies performed in PD experimental models suggest that cdk5/p25 plays a predominant role. In the present study, we examined the gyrus cinguli of cases with PD and compared them with age-matched controls, and we demonstrated an activation of the calpain/cdk5 pathway. We found an increase in the p25/p35 immunoreactivity ratio and in the expression of transcription factor E2F-1. Our results implicate the cdk5/p25 pathway and re-entry into the cell cycle in the process of neuronal loss in patients with PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17977053     DOI: 10.1016/j.parkreldis.2007.09.005

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  24 in total

1.  Next-generation sequencing reveals regional differences of the α-synuclein methylation state independent of Lewy body disease.

Authors:  L de Boni; S Tierling; S Roeber; J Walter; A Giese; Hans A Kretzschmar
Journal:  Neuromolecular Med       Date:  2011-11-01       Impact factor: 3.843

Review 2.  Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death.

Authors:  Jaume Folch; Felix Junyent; Ester Verdaguer; Carme Auladell; Javier G Pizarro; Carlos Beas-Zarate; Mercè Pallàs; Antoni Camins
Journal:  Neurotox Res       Date:  2011-10-01       Impact factor: 3.911

3.  Activation of ataxia telangiectasia muted under experimental models and human Parkinson's disease.

Authors:  Antoni Camins; Javier G Pizarro; Daniel Alvira; Javier Gutierrez-Cuesta; Aurelio Vazquez de la Torre; Jaume Folch; Francesc X Sureda; Ester Verdaguer; Felix Junyent; Joaquín Jordán; Isidre Ferrer; Mercè Pallàs
Journal:  Cell Mol Life Sci       Date:  2010-05-26       Impact factor: 9.261

Review 4.  Cdk5: mediator of neuronal development, death and the response to DNA damage.

Authors:  Jinqiu Zhu; Wenming Li; Zixu Mao
Journal:  Mech Ageing Dev       Date:  2011-05-11       Impact factor: 5.432

Review 5.  The c-Abl inhibitor in Parkinson disease.

Authors:  Zhi-Hua Zhou; Yun-Fan Wu; Xue-Min Wang; Yong-Zhu Han
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

Review 6.  Deregulated Cdk5 activity is involved in inducing Alzheimer's disease.

Authors:  Varsha Shukla; Susan Skuntz; Harish C Pant
Journal:  Arch Med Res       Date:  2012-11-07       Impact factor: 2.235

7.  The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson׳s disease therapy.

Authors:  Carol A Lazzara; Rebeccah R Riley; Anand Rane; Julie K Andersen; Yong-Hwan Kim
Journal:  Brain Res       Date:  2015-06-26       Impact factor: 3.252

8.  Spectrin Breakdown Products (SBDPs) as Potential Biomarkers for Neurodegenerative Diseases.

Authors:  Xiao-Xin Yan; Andreas Jeromin; A Jeromin
Journal:  Curr Transl Geriatr Exp Gerontol Rep       Date:  2012-06

9.  Characterization of a novel human CDK5 splicing variant that inhibits Wnt/beta-catenin signaling.

Authors:  Qiang Li; Xianghua Liu; Mingjun Zhang; Guangming Ye; Qian Qiao; Yichen Ling; Yanhua Wu; Yuanyuan Zhang; Long Yu
Journal:  Mol Biol Rep       Date:  2009-08-20       Impact factor: 2.316

Review 10.  Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration.

Authors:  P S Vosler; C S Brennan; J Chen
Journal:  Mol Neurobiol       Date:  2008-08-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.